Dilantin Infatabs Dosage
Generic name: phenytoin
Dosage form: tablet, chewable
- Dilantin capsule, extended release
- Dilantin Kapseals capsule, extended release
- Dilantin-125 oral suspension
This dosage information does not include all the information needed to use Dilantin Infatabs safely and effectively. See full prescribing information for Dilantin Infatabs.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
When given in equal doses, Dilantin Infatabs yield higher plasma levels than Dilantin Kapseals®. For this reason serum concentrations should be monitored and care should be taken when switching a patient from the sodium salt to the free acid form.
Dilantin® Kapseals® is formulated with the sodium salt of phenytoin. The free acid form of phenytoin is used in Dilantin-125 Suspensions and Dilantin Infatabs. Because there is approximately an 8% increase in drug content with the free acid form over that of the sodium salt, dosage adjustments and serum level monitoring may be necessary when switching from a product formulated with the free acid to a product formulated with the sodium salt and vice versa.
Not for once-a-day dosing.
Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations may be necessary for optimal dosage adjustments—the clinically effective serum level is usually 10–20 mcg/mL. With recommended dosage, a period of seven to ten days may be required to achieve steady-state blood levels with phenytoin and changes in dosage (increase or decrease) should not be carried out at intervals shorter than seven to ten days.
Dilantin Infatabs can be either chewed thoroughly before being swallowed or swallowed whole.
Patients who have received no previous treatment may be started on two Infatabs three times daily, and the dose is then adjusted to suit individual requirements. For most adults, the satisfactory maintenance dosage will be six to eight Infatabs daily; an increase to twelve Infatabs daily may be made, if necessary.
Dosing in Special Populations
Patients with Renal or Hepatic Disease
Due to an increased fraction of unbound phenytoin in patients with renal or hepatic disease, or in those with hypoalbuminemia, the interpretation of total phenytoin plasma concentrations should be made with caution. Unbound phenytoin concentrations may be more useful in these patient populations.
Phenytoin clearance is decreased slightly in elderly patients and lower or less frequent dosing may be required.
Initially, 5 mg/kg/day in two or three equally divided doses, with subsequent dosage individualized to a maximum 300 mg daily. A recommended daily maintenance dosage is usually 4 to 8 mg/kg. Children over 6 years old and adolescents may require the minimum adult dose (300 mg/day). If the daily dosage cannot be divided equally, the larger dose should be given before retiring.
- Dilantin Side Effects
- Dilantin Drug Interactions
- Dilantin (phenytoin) consumer information
- Dilantin (phenytoin sodium) capsule, extended release dosage information
- Dilantin Kapseals (phenytoin sodium) capsule, extended release dosage information
- Dilantin-125 (phenytoin) oral suspension dosage information
- Phenytek (phenytoin sodium) capsule, extended release dosage information
- Phenytoin dosage information
- Phenytoin consumer information
- Phenytoin Sodium injection dosage information